The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: A phase II NEOTAX study.
Nuriye Ă–zdemir
No relevant relationships to disclose
Huseyin Abali
No relevant relationships to disclose
Murat Vural
No relevant relationships to disclose
Suayib Yalcin
No relevant relationships to disclose
Berna Oksuzoglu
No relevant relationships to disclose
Burak Civelek
No relevant relationships to disclose
Dilek Oguz
No relevant relationships to disclose
Birol Bostanci
No relevant relationships to disclose
Bulent Yalcin
No relevant relationships to disclose
Nurullah Zengin
No relevant relationships to disclose